Datar Cancer Genetics is a multi-national molecular oncology facility focused on innovative test solutions for cancer screening, diagnosis and therapy guidance. Their aim is to help patients through the use of molecular oncology and personalised medicine.
The non-invasive blood-based test portfolio supports clinicians to select personalised therapies that will help improve patient outcomes. Datar Cancer Genetics has received two Breakthrough Device Designations from the US-FDA for its early detection tests for breast and prostate cancer.
The Clinical Laboratory Improvement Amendments of 1988 (CLIA) has certified Datar Cancer Genetics clinical laboratory in Guildford UK, and the College of American Pathologists (CAP) has granted it accreditation. It is equipped with state-of-the-art machines and analytics. The laboratory is registered with CQC and is an applicant with UKAS.
The centre provides a wide range of services in molecular genomics and Circulating Tumour Cell (CTC) analysis for cancer patients.
You can request testing from your healthcare provider. Alternatively, contact Datar Cancer Genetics and they will put you in touch with their clinical partners.
Cancer screening, diagnosis and therapy guidance products Trucheck™, Cancertrack™, Exacta™, Trublood™ and Celldx™
We use cookies to improve your experience on our site. Learn more.
We use cookies to enhance your browsing experience and enable essential functions on our website. Some cookies are categorised as "Necessary" are automatically stored on your browser as they are crucial for the basic operation of the site - they can no be adjusted using these tools. Additionally, we use third-party cookies to help us analyse your usage of the website. These cookies are stored in your browser only with your prior consent. You have the option to enable or disable some or all of these cookies.